Patents by Inventor Hartmut Strobel

Hartmut Strobel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acylated arylcycloalkylamines and their use as pharmaceuticals
    Publication number: 20040082628
    Abstract: The present invention relates to acylated arylcycloalkylamines, to pharmaceutical compositions comprising such compounds, to methods for the stimulation of the expression of endothelial NO synthase, and methods of treatment comprising administering such compounds.
    Type: Application
    Filed: August 7, 2003
    Publication date: April 29, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Hartmut Strobel, Paulus Wohlfart, Peter Below
  • Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them
    Publication number: 20040063690
    Abstract: The present invention relates to compounds of formula I: 1
    Type: Application
    Filed: October 1, 2003
    Publication date: April 1, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GmBH
    Inventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel
  • Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them
    Publication number: 20040048850
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 have the meanings given in the claims. Said compounds are valuable active agents in medicaments for the treatment and prophylaxis of diseases, for example cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) arc able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the treatment and prophylaxis ofisorders associated with an impaired cGMP balance. The invention also relates to methods for producing compounds of formula (I), to their use in the treatment and prophylaxis of the above diseases and in the preparation of medicaments for such diseases, and to pharmaceutical preparations containing the compounds of formula (I).
    Type: Application
    Filed: September 12, 2003
    Publication date: March 11, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schoenafinger, Hartmut Strobel
  • 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
    Publication number: 20040019114
    Abstract: The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) 1
    Type: Application
    Filed: July 22, 2003
    Publication date: January 29, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Paulus Wohlfart, Teri Suzuki, Ramalinga M. Dharanipragada, Alena Safarova, Armin Walser, Hartmut Strobel
  • Substituted 4-amino-2-aryl-tetrahydoquinazolines, their preparation, their use and pharmaceutical preparations comprising them
    Patent number: 6660746
    Abstract: The present invention relates to compounds of formula I: wherein R1, R2, and R3 have the meanings indicated in the specification, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases such as cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses, or atherosclerosis. Compounds of formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for the preparation of compounds formula I, methods of therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, and pharmaceutical compositions which comprise at least one compound of formula I.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: December 9, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
  • Substituted 4-amino-2-aryl-cyclopenta[d]pyrimidines, their production and use and pharmaceutical preparations containing same
    Patent number: 6627628
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 have the meanings given in the claims. Said compounds are valuable active agents in medicaments for the treatment and prophylaxis of diseases, for example cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the treatment and prophylaxis ofisorders associated with an impaired cGMP balance. The invention also relates to methods for producing compounds of formula (I), to their use in the treatment and prophylaxis of the above diseases and in the preparation of medicaments for such diseases, and to pharmaceutical preparations containing the compounds of formula (I).
    Type: Grant
    Filed: May 17, 2001
    Date of Patent: September 30, 2003
    Assignee: Aventis Pharma Deutschland, GmbH
    Inventors: Ursula Schindler, Karl Schoenafinger, Hartmut Strobel
  • Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators
    Publication number: 20030171352
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: January 24, 2003
    Publication date: September 11, 2003
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schoenafinger, Hartmut Strobel
  • 4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
    Patent number: 6617359
    Abstract: The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) to the said mammal.
    Type: Grant
    Filed: February 13, 2002
    Date of Patent: September 9, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Paulus Wohlfart, Teri Suzuki, Ramalinga M. Dharanipragada, Alena Safarova, Armin Walser, Hartmut Strobel
  • Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments
    Patent number: 6613772
    Abstract: Compounds of the formula I in which R1, R2, R3 and Ar have the meanings indicated in the claims, are suitable for the production of pharmaceuticals, for example for the prophylaxis and therapy of cardiovascular diseases such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: September 2, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel, Peter Schindler
  • Pyrazole derivatives, their preparation and their use in pharmaceuticals
    Publication number: 20030105336
    Abstract: The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: 1
    Type: Application
    Filed: September 24, 2002
    Publication date: June 5, 2003
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel
  • Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators
    Patent number: 6548547
    Abstract: The present invention relates to compounds of the formula I in which A1, A2, R2 and R3 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention relates to the use of compounds of the formula I for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, novel compounds of the formula I, pharmaceutical preparations comprising them and processes for their preparation.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: April 15, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schoenafinger, Hartmut Strobel
  • Method for detecting oxidized forms of soluble guanylate cyclase and a method for screening for activators of soluble guanylate cyclase having oxidized heme iron
    Publication number: 20030054433
    Abstract: The invention relates to methods for detecting a soluble guanylate cyclase whose heme iron is in the trivalent oxidation state, and to methods for finding chemical substances which stimulate the activity of a soluble guanylate cyclase when the heme iron of at least part of this soluble guanylate cyclase is oxidized to the trivalent state and also to diagnostic aids or kits for detecting a soluble guanylate cyclase with trivalent heme iron. Further, the invention relates methods for detecting a soluble guanylate cyclase lacking a heme group, and to methods for finding chemical substances which stimulate the activity of a soluble guanylate cyclase lacking a heme group.
    Type: Application
    Filed: October 10, 2002
    Publication date: March 20, 2003
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Hartmut Strobel, Peter Schindler, Alexander Muelsch
  • Acylated indanyl amines and their use as pharmaceuticals
    Publication number: 20030055093
    Abstract: The present invention relates to acylated indanyl amines according to the general formula (I) 1
    Type: Application
    Filed: February 13, 2002
    Publication date: March 20, 2003
    Inventors: Hartmut Strobel, Paulus Wohlfart, Alena Safarova, Armin Walser, Teri Suzuki, Karl Schonafinger, Ramalinga M. Dharanipragada
  • Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents
    Publication number: 20030022935
    Abstract: The present invention relates to compounds of general formula (I), 1
    Type: Application
    Filed: February 13, 2002
    Publication date: January 30, 2003
    Inventors: Hartmut Strobel, Paulus Wohlfart
  • 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical
    Publication number: 20030022939
    Abstract: The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) 1
    Type: Application
    Filed: February 13, 2002
    Publication date: January 30, 2003
    Inventors: Paulus Wohlfart, Teri Suzuki, Ramalinga M. Dharanipragada, Alena Safarova, Armin Walser, Hartmut Strobel
  • Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents
    Publication number: 20030008915
    Abstract: The present invention relates to compounds according to the general formula (I), 1
    Type: Application
    Filed: February 13, 2002
    Publication date: January 9, 2003
    Inventors: Hartmut Strobel, Paulus Wohlfart
  • Method for detecting oxidized forms of soluble guanylate cyclase
    Patent number: 6500631
    Abstract: The invention relates to methods for detecting a soluble guanylate cyclase whose heme iron is in the trivalent oxidation state, and to methods for finding chemical substances which stimulate the activity of a soluble guanylate cyclase when the heme iron of at least part of this soluble guanylate cyclase is oxidized to the trivalent state and also to diagnostic aids or kits for detecting a soluble guanylate cyclase with trivalent heme iron. Further, the invention relates methods for detecting a soluble guanylate cyclase lacking a heme group, and to methods for finding chemical substances which stimulate the activity of a soluble guanylate cyclase lacking a heme group.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: December 31, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Hartmut Strobel, Peter Schindler, Alexander Muelsch
  • Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
    Publication number: 20020061887
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: November 28, 2001
    Publication date: May 23, 2002
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel
  • Substituted isoindolones and their use as cyclic GMP modulators in medicaments
    Patent number: 6344468
    Abstract: The present invention relates to substituted isoindolone derivatives of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for these, and also pharmaceutical preparations which comprise compounds of the formula I.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: February 5, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schoenafinger, Hartmut Strobel, Viola Groehn
  • Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them
    Patent number: 6335334
    Abstract: The present invention relates to compounds of the formula I wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the formula I.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: January 1, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel